BridgeBio Pharma (BBIO) PT Raised to $110 at TD Cowen
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
- Wall Street ends lower as Alphabet revenue miss revives AI capex jitters
- Alphabet shares tumble 10% as earnings miss overshadows cloud boom
- Microsoft rises premarket as cloud strength drives earnings beat
- Caterpillar shares slump 10% despite earnings beat amid rapid AI buildout
- DoorDash to acquire Instacart in $17 billion deal
Tweet
Share
E-mailGet Alerts BBIO Hot Sheet
Price: $70.73 -0.13%
Rating Summary:
25 Buy, 3 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 18 | Down: 27 | New: 16
Rating Summary:
25 Buy, 3 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 18 | Down: 27 | New: 16
Join SI Premium – FREE
TD Cowen analyst Tyler Van Buren raised the price target on BridgeBio Pharma (NASDAQ: BBIO) to $110.00 (from $95.00) while maintaining a Buy rating.
You May Also Be Interested In
- BridgeBio Pharma Inc. (BBIO) Tops Q3 EPS by 14c
- Baxter International (BAX) PT Lowered to $25 at Stifel
- Unilever plc (ULVR:LN) (UL) PT Lowered to GBP55 at TD Cowen
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
